A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors
Authors:
- 13 May 2009
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 28 (4) , 509-515
Abstract
Summary Purpose: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of MN-209, a novel vascular disrupting agent, in patients with advanced solid tumors. Study Design: MN-029 was administered weekly for three consecutive weeks out of four; two cycles were planned. Dose escalation proceeded by 100% per toxicity criteria. Intra-patient dose escalation was permitted. Results: Twenty patients received a total of 151 infusions of MN-029. No DLTs or grade 4 toxicities occurred. The most common adverse events were nausea, vomiting, arthralgias, and headache. One patient developed acute substernal chest pain 4 days after his first dose of MN-029 and was removed from the study. An MTD was not determined. The recommended phase II dose was identified as 180 mg/m2/week. One patient with advanced pancreatic cancer attained a partial response lasting 10 weeks. Conclusions: MN-029 was well tolerated in this schedule. Further development of this class of agents is warranted, especially in combination with other anti-cancer treatments.Keywords
This publication has 22 references indexed in Scilit:
- Tumour vascular disrupting agents: combating treatment resistanceBritish Journal of Radiology, 2008
- Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectivesThe Lancet Oncology, 2008
- Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsInvestigational New Drugs, 2008
- Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in OncologyJournal of Clinical Oncology, 2007
- Vascular disrupting agents in clinical developmentBritish Journal of Cancer, 2007
- Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional TherapiesCancer Research, 2006
- Promise of New Vascular-Disrupting Agents Balanced With Cardiac Toxicity: Is It Time for Oncologists to Get to Know Their Cardiologists?Journal of Clinical Oncology, 2006
- Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid TumorsJournal of Clinical Oncology, 2006
- Sensitization of Tumor-Associated Endothelial Cell Apoptosis by the Novel Vascular-Targeting Agent ZD6126 in Combination with CisplatinClinical Cancer Research, 2004
- Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic ResultsJournal of Clinical Oncology, 2003